On the pulse of ASCO: pricing and clinical trial access
New survey data from MedPanel, compiled exclusively for pharmaphorum, has revealed US physicians’ thoughts on the topics set to dominate ASCO.
Ahead of 2019’s annual American Society of Clinical Oncology conference, taking place in Chicago from 31 May to 2 June, the survey asked 100 US physicians – 62% of whom said they would be attending the conference – for their views on clinical trial access and pricing, two subjects dominating oncology at the moment.
A featured session at ASCO this year is ‘Overcoming Barriers to Clinical Trial Enrollment’, so one of the survey questions looked to see what physicians felt could have the biggest impact on increasing patient participation in clinical trials. The results were fairly evenly split, but the majority noted the importance of providing physicians and allied healthcare professionals with additional educational training regarding the benefits of clinical trials and outreach to potential patients.
A featured session during the upcoming 2019 ASCO Annual Meeting is Overcoming Barriers to Clinical Trial Enrollment. Of the potential solutions listed below, which two options do you feel could have the most impact on increasing patient participation in clinical trials?
Meanwhile, with drug pricing dominating headlines in the US, it’s perhaps no surprise that most physicians thought that pricing debates are set to have an impact on discussions at ASCO. Forty-nine percent thought this would be a ‘moderate’ impact and 15% felt the impact would be ‘significant’.
How much impact do you believe cancer medication pricing and access debates will have on conversations during the 2019 ASCO Annual Meeting?
Fifty-seven percent ‘strongly agreed’ that pricing and access are a significant issue for cancer patients and physicians, with only 3% outright disagreeing with this statement. In addition, only 14% of physicians said they would never avoid prescribing a cancer medication if they felt the price was too high.
Do you avoid prescribing a cancer medication if you feel it is priced too high?
Nevertheless, clinical trial results were a far more important factor than pricing in influencing prescribing decisions – and 56% of those surveyed said that Health Technology Assessment (HTA) decisions never affect their prescribing of cancer medicines.
Which of the following factors has the most influence on your prescribing of oncology medications?
Do market access and Health Technology Assessment (HTA) decisions from The National Institute for Health and Care Excellence (NICE), Institute for Clinical and Economic Review (ICER), Institute for Quality and Efficiency in Healthcare (IQWiG) restrict your prescribing of oncology mediations?
pharmaphorum will be onsite at ASCO with full coverage across the weekend. For more information see here.
MedPanel is a full-service, healthcare market research firm with more than 20 years of global industry experience. They provide research services across the healthcare spectrum. For more information, please visit www.medpanel.com.